Insights and lessons learned about operationalising the use of real world data.
Advances in technology, from the massive storage and computing options now available through cloud computing to advances in algorithmic processing, have empowered organisations to consider secondary RWD sources as viable options for evidence generation across a wide spectrum of use cases.
Within the last few years, the exploration and practical use of secondary data has grown exponentially and is now fueling a new wave of digital disruption. New insights we never thought possible are now becoming achievable. However, operationalising this data from a research perspective has challenges and risks that need to be addressed very carefully to achieve success.
From my own research, as a senior technologist, below are ten lessons learned:
- Ensure an overarching data strategy is defined with insight from your clinical stakeholders. Suggest forming a Data Center of Excellence (CoE) to provide the appropriate governance around alignment and general use, policy definition, accountabilities and decision trees to ensure the data is managed well. Start small and mature with time, refer to the Information Systems Audit and Control Association (ISACA) for classification, if required.
- Select data that provides differentiation. There are many different types of secondary data available today, most commonly, claims and EHR data. Be sure to select data that is “fit-for-purpose” to the intended research needs.
- Look closely at data quality. From a data quality perspective, ensure that the schema is reviewed with detail to ensure the data fields match to the intended research need.
- Perform preliminary analysis. To ensure the robustness of the data, perform preliminary analysis to ensure the demographic “counts” match the requirements/protocol of the research. Also, if you are planning to utilise Natural Language Processing (NLP) for “free-text” analysis, as an example physician note extraction from EMR systems, work with your data provider to receive a “data density” report to ensure the investment in NLP is warranted based on the results of the report.
- Understand the power of linking datasets. Each data set has its strengths and weaknesses and commonly they will present a more holistic longitudinal view if linked together. For planning purposes as it relates to data linking, a Venn diagram works well to understand the logical relation of records between linked data sets.
- Consider the details when linking data. From a linking perspective, consider the Observational Medical Outcomes Partnership (OMOP) standardisation, as the more standardised the schema is, the more flexible to serve many use cases within the enterprise. Ensure the data has not been tokenised beforehand, as linking may not be possible. To ensure proper linking, the fields need to be available from both sources, then the appropriate hashing algorithm can be utilised to perform the tokenisation across all sources of data. If you are considering connecting to external systems, such as EMR systems, agree to an appropriate standard, such as the Fast Healthcare Interoperability Resources (FHIR) standard to ensure the data formats and elements are commonly understood for exchanging data.
- Understand the cost model. Cost is usually measured across the following three areas; how many therapeutic areas are contained in the dataset, the “refresh/updates” (assume more from prospective studies) and lastly, any links that need to be established to other data sources. Ensure that there is not any hidden development cost for data extraction. Lastly, ensure that the targeted data is not already present within your organisation, as data redundancy has been rising with duplicative data spend within the enterprise.
- Maintain compliance with GDPR and applicable data protection. Most often the data in scope is anonymised and falls outside the scope of the GDPR. However, it can be difficult to fully anonymise data and de-identified data (pseudonymised data) falls within the scope of the GDPR. The entities involved need to ensure they comply with relevant data protection obligations and that data controller and data processor roles are clearly assigned. A data controller determines the purposes and means of the processing of personal data, simply put “who is in charge and leading the way”. A data processor is responsible for processing the data on behalf of the data controller, simply put “following the instructions of the data controller”. It is important to ensure the appropriate agreements including data processing agreements are in place between the relevant parties and that there is an appropriate mechanism for the transfer of personal data, if applicable.
- Plan for secure transmission. From a data extraction perspective, ensure the appropriate secure transmission is applicable to satisfy compliance. Most often, data providers have “cloud to cloud” secure transmission as a preferred choice however Secure File Transfer Protocol (SFTP) can still be used as a source of transmission and lastly, most data providers now have their own secure portal in which to download data, as always ensure appropriate safeguards are in place for encryption in transit and at rest.
- Ensure appropriate training is setup and conducted. From a clinical perspective, standard operating procedures (SOP) work well to define how to interact with the data; that is understanding the operational standards to utilise the data. These SOPs should be part of your overall governance process.
![](https://icon.widen.net/content/bf27d696-0abb-44ba-8782-81ae4c6141bb/web/Capobianco_Bruce_1.png?crop=yes&w=240&h=240&itok=wM5FowEw)
Bruce Capobianco
Bruce has over 15 years’ experience in the architecture, development and implementation of complex big data solutions. He leads a team to develop, enhance, and maintain RWE technology solutions for ICON clients. He is experienced in identifying and implementing secure, usable and enduring technologies that augment business processes and optimise productivity.
Real World Data insights
ICON's real world data (RWD) continues to drive healthcare and research discussions and decisions. Stay up to date with the latest information that regulators, payers and providers demand.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel